{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T08:21:18Z","timestamp":1790324478332,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T00:00:00Z","timestamp":1706832000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K16136"],"award-info":[{"award-number":["20K16136"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K08430"],"award-info":[{"award-number":["23K08430"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K15143"],"award-info":[{"award-number":["23K15143"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological Sciences"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.jphs.2024.02.002","type":"journal-article","created":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T16:33:32Z","timestamp":1706891612000},"page":"218-224","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Characterization of cardiovascular profile of anti-influenza drug peramivir: A reverse-translational study using the isoflurane-anesthetized dog"],"prefix":"10.1016","volume":"154","author":[{"given":"Ryuichi","family":"Kambayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Izumi-Nakaseko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Takei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jphs.2024.02.002_bib1","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jiac.2014.07.006","article-title":"Post-marketing safety and effectiveness evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir (I): a drug use investigation","volume":"20","author":"Komeda","year":"2014","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jphs.2024.02.002_bib2","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jiac.2014.11.009","article-title":"Post-marketing safety and effectiveness evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir. II: a pediatric drug use investigation","volume":"21","author":"Komeda","year":"2015","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jphs.2024.02.002_bib3","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1128\/AAC.00132-11","article-title":"Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection","volume":"56","author":"Sugaya","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jphs.2024.02.002_bib4","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3389\/fmicb.2016.00450","article-title":"A novel intravenous neuraminidase inhibitor for treatment of acute influenza infections","volume":"7","author":"Alame","year":"2016","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jphs.2024.02.002_bib5","doi-asserted-by":"crossref","first-page":"5267","DOI":"10.1128\/AAC.00360-11","article-title":"S-021812 Clinical Study Group. Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection","volume":"55","author":"Kohno","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jphs.2024.02.002_bib6","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1128\/AAC.00474-10","article-title":"S-021812 Clinical Study Group. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection","volume":"54","author":"Kohno","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jphs.2024.02.002_bib7","article-title":"European medicines agency","year":"2018","journal-title":"Assess Rep Alpivab Int Non-Propriet Name: peramivir"},{"key":"10.1016\/j.jphs.2024.02.002_bib8","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jphs.2020.10.001","article-title":"In vivo comparison of dl-sotalol-induced electrocardiographic responses among halothane anesthesia, isoflurane anesthesia with nitrous oxide, and conscious state","volume":"145","author":"Saito","year":"2021","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.jphs.2024.02.002_bib9","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jphs.2020.12.010","article-title":"In vivo analysis of concentration-dependent effects of halothane or isoflurane inhalation on the electrocardiographic and hemodynamic variables in dogs","volume":"145","author":"Saito","year":"2021","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.jphs.2024.02.002_bib10","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/clpt.2014.155","article-title":"Differentiating drug-induced multichannel block on the electrocardiogram: randomized study of dofetilide, quinidine, ranolazine, and verapamil","volume":"96","author":"Johannesen","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jphs.2024.02.002_bib11","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1038\/bjp.2008.240","article-title":"Sensitive and reliable proarrhythmia in vivo animal models for predicting drug-induced torsades de pointes in patients with remodelled hearts","volume":"154","author":"Sugiyama","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jphs.2024.02.002_bib12","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jphs.2023.05.003","article-title":"Characterization of electropharmacological profile of an anti-atrial fibrillatory drug vernakalant along with potential risk toward torsade de pointes: translational studies using isoflurane-anesthetized dogs and isolated rat aortic preparations","volume":"152","author":"Goto","year":"2023","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.jphs.2024.02.002_bib13","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0022-0736(99)90074-2","article-title":"Transmural dispersion of repolarization and arrhythmogenicity: the Brugada syndrome versus the long QT syndrome","volume":"32","author":"Antzelevitch","year":"1999","journal-title":"J Electrocardiol"},{"key":"10.1016\/j.jphs.2024.02.002_bib14","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1254\/jjp.88.414","article-title":"Effects of a typical IKr channel blocker sematilide on the relationship between ventricular repolarization, refractoriness and onset of torsades de pointes","volume":"88","author":"Sugiyama","year":"2002","journal-title":"Jpn J Pharmacol"},{"key":"10.1016\/j.jphs.2024.02.002_bib15","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s12012-013-9202-6","article-title":"Cardiohemodynamic and electrophysiological effects of anti-influenza drug oseltamivir in vivo and in vitro","volume":"13","author":"Kitahara","year":"2013","journal-title":"Cardiovasc Toxicol"},{"key":"10.1016\/j.jphs.2024.02.002_bib16","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2131\/jts.41.439","article-title":"Electropharmacological effects of amantadine on cardiovascular system assessed with J-Tpeak and Tpeak-Tend analysis in the halothane-anesthetized beagle dogs","volume":"41","author":"Cao","year":"2016","journal-title":"J Toxicol Sci"},{"key":"10.1016\/j.jphs.2024.02.002_bib17","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1006\/taap.1998.8494","article-title":"Effects of gastrointestinal prokinetic agents, TKS159 and cisapride, on the in situ canine heart assessed by cardiohemodynamic and electrophysiological monitoring","volume":"152","author":"Sugiyama","year":"1998","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.jphs.2024.02.002_bib18","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0021-5198(19)30812-1","article-title":"Effects of a class III antiarrhythmic drug, dofetilide, on the in situ canine heart assessed by the simultaneous monitoring of hemodynamic and electrophysiological parameters","volume":"81","author":"Satoh","year":"1999","journal-title":"Jpn J Pharmacol"},{"key":"10.1016\/j.jphs.2024.02.002_bib19","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0160-5402(89)90015-6","article-title":"An improved method to correct the QT interval of the electrocardiogram for changes in heart rate","volume":"22","author":"Van de Water","year":"1989","journal-title":"J Pharmacol Methods"},{"key":"10.1016\/j.jphs.2024.02.002_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.593021","article-title":"Translational studies on anti-atrial fibrillatory action of oseltamivir by its in vivo and in vitro electropharmacological analyses","volume":"12","author":"Kambayashi","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jphs.2024.02.002_bib20","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3851\/IMP3104","article-title":"Pharmacokinetics and safety of intravenous peramivir, neuraminidase inhibitor of influenza virus, in healthy Japanese subjects","volume":"22","author":"Saisho","year":"2017","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jphs.2024.02.002_bib21","first-page":"H793","article-title":"Regional differences in effects of E-4031 within the sinoatrial node","volume":"276","author":"Kodama","year":"1999","journal-title":"Am J Physiol"},{"key":"10.1016\/j.jphs.2024.02.002_bib22","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1161\/01.RES.72.1.75","article-title":"Rate-dependent prolongation of cardiac action potentials by a methanesulfonanilide class III antiarrhythmic agent. Specific block of rapidly activating delayed rectifier K+ current by dofetilide","volume":"72","author":"Jurkiewicz","year":"1993","journal-title":"Circ Res"},{"key":"10.1016\/j.jphs.2024.02.002_bib24","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jphs.2021.11.002","article-title":"Simultaneous analyses of hemodynamic and electrophysiological effects of oseltamivir along with its pharmacokinetic profile using the canine paroxysmal atrial fibrillation model","volume":"148","author":"Kambayashi","year":"2022","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.jphs.2024.02.002_bib25","doi-asserted-by":"crossref","first-page":"i133","DOI":"10.1093\/europace\/euaa404","article-title":"Cycle length statistics during human atrial fibrillation reveal refractory properties of the underlying substrate: a combined in silico and clinical test of concept study","volume":"23","author":"Unger","year":"2021","journal-title":"Europace"},{"key":"10.1016\/j.jphs.2024.02.002_bib26","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1093\/europace\/eul113","article-title":"Analysis of surface electrocardiograms in atrial fibrillation: techniques, research, and clinical applications","volume":"8","author":"Bollmann","year":"2006","journal-title":"Europace"},{"key":"10.1016\/j.jphs.2024.02.002_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s004210050550","article-title":"Plasma volume changes during and after acute variations of body hydration level in humans","volume":"80","author":"Jimenez","year":"1999","journal-title":"Eur J Appl Physiol Occup Physiol"},{"key":"10.1016\/j.jphs.2024.02.002_bib28","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1152\/ajplegacy.1961.201.5.791","article-title":"Renal hemodynamics during hyperthermia caused by exposure to high environmental temperature","volume":"201","author":"Kanter","year":"1961","journal-title":"Am J Physiol"},{"key":"10.1016\/j.jphs.2024.02.002_bib29","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/cpt.2137","article-title":"Translational models and tools to reduce clinical trials and improve regulatory decision making for QTc and proarrhythmia risk (ICH E14\/S7B Updates)","volume":"109","author":"Strauss","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jphs.2024.02.002_bib30","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1161\/CIRCEP.107.691931","article-title":"Fever accentuates transmural dispersion of repolarization and facilitates development of early afterdepolarizations and torsade de pointes under long-QT Conditions","volume":"1","author":"Burashnikov","year":"2008","journal-title":"Circ Arrhythm Electrophys"},{"key":"10.1016\/j.jphs.2024.02.002_bib31","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jacc.2010.01.001","article-title":"Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation","volume":"55","author":"Drew","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jphs.2024.02.002_bib32","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0733-8651(18)30650-7","article-title":"Myocardial stimulation threshold in patients with cardiac pacemakers: effect of physiologic variables, pharmacologic agents, and lead electrodes","volume":"3","author":"Dohrmann","year":"1985","journal-title":"Cardiol Clin"},{"key":"10.1016\/j.jphs.2024.02.002_bib33","first-page":"239","article-title":"Effects of anti-arrhythmic drugs for pacing threshold and defibrillation threshold","volume":"27","author":"Ishikawa","year":"2011","journal-title":"J Arrhythm"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861324000112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861324000112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T20:23:52Z","timestamp":1742243032000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347861324000112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1347861324000112"],"URL":"https:\/\/doi.org\/10.1016\/j.jphs.2024.02.002","relation":{},"ISSN":["1347-8613"],"issn-type":[{"value":"1347-8613","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of cardiovascular profile of anti-influenza drug peramivir: A reverse-translational study using the isoflurane-anesthetized dog","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jphs.2024.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.","name":"copyright","label":"Copyright"}]}}